Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14771761 | 0.82 | SMN1; SMN2 (0.40) | ALDH1A1KDM4ESMN1; SMN2NFKB1L3MBTL1 | |
| SCHEMBL13832839 | 0.82 | AOC3 (0.37) | ALDH1A1KDM4ESMN1; SMN2AOC3ENPP1 | |
| SCHEMBL25323208 | 0.80 | TLR8 (0.45) | ALDH1A1KDM4ESMN1; SMN2AOC3L3MBTL1 | |
| SCHEMBL30068026 | 0.80 | TLR8 (0.45) | ALDH1A1KDM4ESMN1; SMN2AOC3L3MBTL1 | |
| SCHEMBL31254690 | 0.79 | ALDH1A1 (0.35) | ALDH1A1KDM4ESMN1; SMN2NFKB1L3MBTL1 | |
| SCHEMBL29197262 | 0.79 | S1PR4 (0.41) | ALDH1A1KDM4ESMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL29556850 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2NFKB1L3MBTL1 | |
| SCHEMBL145005 | 0.78 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2NFKB1L3MBTL1 | |
| SCHEMBL11194802 | 0.77 | MAPT (0.43) | ALDH1A1SMN1; SMN2L3MBTL1MAPTMEN1 | |
| SCHEMBL31456731 | 0.77 | KDM4E (0.35) | ALDH1A1KDM4ESMN1; SMN2AOC3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096539-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250145590-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
| CN-113717156-B | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2021238827-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | 南京红云生物科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| EP-2519102-B1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEV CENTER BIOTECHNOLOGY (TW) | 2016-10-19 | — | — | EP | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2519102-A2 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | Development Center For Biotechnology (TW) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080568-A2 | NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-07-07 | — | — | WO | disclosed |
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 3822/4885KDM4E 3671/4885SMN1; SMN2 4750/4885 |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | ALDH1A1 2963/4885KDM4E 1949/4885SMN1; SMN2 3386/4885 |
| US-20250145590-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | USP1, UBA1, SUMO1 | ALDH1A1 575/4885KDM4E 1116/4885SMN1; SMN2 3477/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | ALDH1A1 2963/4885KDM4E 1949/4885SMN1; SMN2 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.